Figure 3(a) showed the antibody level of GRP78 was significantly higher in test group GC patients than that in control group. However, the levels of the anti-GRP78 antibody presented no difference in the subgroup analysis in test group (TNM : I-II vs. III-IV; tumor diameter size: <5 cm vs. ≥5 cm; lymphatic metastasis: yes vs. no; differentiation degree: poor vs. moderate and high). The same results were observed in the validation group and the combination of test and validation group (Figures 3(b) and 3(c)). This evidence concerns the gene HSPA5 and neoplasm.